Ultrasound opens brain barrier to deliver Parkinson's drug in first human test

NCT ID NCT05565443

Recruiting now Disease control Sponsor: InSightec Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether a focused ultrasound device can safely open the blood-brain barrier to deliver a missing enzyme (GCase) directly into the brains of 14 people with Parkinson's disease. The goal is to see if this delivery method is safe and feasible, not yet to prove it works as a treatment. Participants must have a specific genetic mutation linked to Parkinson's.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: recombinant glucocerebrosidase (GCase) enzyme
What this could lead to: If successful, this could lead to a new way to deliver treatments directly to the brain for Parkinson's disease, potentially slowing disease progression.
What could go wrong: This is an early, small trial (14 people) focused on safety and feasibility, not yet on effectiveness. The procedure involves opening the blood-brain barrier, which carries risks like bleeding or swelling.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSONS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSONS DISEASE

Contacts and locations

Locations

Sunybrook Research Institute
RECRUITING

Toronto, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.